Colorectal Surgeon Dr. Julio Garcia-Aguilar, MD, PhD (seated) with nurse Kieran Kelleher BSN-RN. Dr. Garcia-Aguilar and the colorectal service at MSK are experts at the watch and wait approach to ...
Total neoadjuvant treatment (TNT) may offer a promising alternative to surgery for patients with stage I rectal cancer (S1RC), a small study finds. 1 Among patients treated, TNT achieved a 93.7% ...
Neoadjuvant treatment with a programmed cell death 1 (PD-1) inhibitor induces clinical complete response and leads to organ preservation in a high proportion of patients with early-stage, mismatch ...
New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery and radiation for some forms of cancer. Nearly 80% of patients who suffered from a ...
The Brighterside of News on MSN
Groundbreaking clinical trial cures cancer in 100% of patients
In a clinical trial involving 14 participants, immunotherapy on its own effectively eradicated rectal cancer. This ...
Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data ...
Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...
More young adults are also being diagnosed, according to Yale Medicine and the Cancer Research Institute. According to the ...
A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn ...
Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of 20 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback